Skip to content

Anika Therapeutics ANIK Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Bioventus logo
BioventusBVS
$0+100%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$14K-62.2%
Globus Medical logo
Globus MedicalGMED
-$2.45M+6.3%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
-$115K+83.5%
Avanos Medical logo
Avanos MedicalAVNS
-$100K+50.0%
Enovis logo
EnovisENOV
$75K-85.8%

Other financials

Income statement

See full
Revenue$29.6M+13.2%
Net income-$5.1M-3.8%

Balance sheet

See full
Cash & equivalents$41.0M-23.1%
Total debt$25.7M+1.2%
Total equity$133.9M-9.8%
Total assets$179.4M-5.9%

Cash flow

See full
Operating cash flow-$4.8M-3,628%
CapEx$1.4M-49.3%
Free cash flow-$6.3M-112%

Valuation

See full
Market cap$204.37M+31.6%
Enterprise value$189.09M+48.7%
P/S1.8×+0.1×

Profitability

See full
Net margin-9.8%-4.4pp
FCF margin0.9%

Returns & leverage

See full
Return on equity-8%-3.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.3×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Anika Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Anika Therapeutics's gain/loss on asset sales?
Anika Therapeutics (ANIK) reported gain/loss on asset sales of $52K in Q1 2026.
How has Anika Therapeutics's gain/loss on asset sales changed year-over-year?
Anika Therapeutics's gain/loss on asset sales decreased by 82.7% year-over-year, from $300K to $52K.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.